KBI, ReForm partnership about ‘bringing better biologics to patients,’ says CEO

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Sinhyu)
(Image: Getty/Sinhyu)
KBI will provide services to ReForm to further develop and validate its biologic formulation platform and in turn, will gain access to ReForm’s proprietary excipient technologies.

KBI a Durham, NC-based contract development and manufacturing organization (CDMO) has partnered with ReForm Biologics, a pharmaceutical technology company developing platforms to improve biologic formulations.

As part of the strategic partnership – financial detail of which were not disclosed – KBI has made an equity investment in ReForm Biologics.

“We chose to engage with KBI because they are a technology-driven company, and growing organization with a great culture,”​ John M. Sorvillo, PhD, CEO of ReForm Biologics told Outsorucing-Pharma.com.

“This collaboration is about bringing better biologics to patients,” ​he said.

Reform’s technologies involve stability-enhancing excipients that Sorvillo said prevent aggregation and particle formation, which increases manufacturing efficiency and product shelf life   

Additionally, Reform’s formulation technology extends product lifecycles and offer product differentiating formulations – a benefit for drug developers Sovillo explained.

“We executed this deal because it will provide competitive advantages to KBI’s clients, it advances and expands the usage of Reform’s technology to many more biologics in biopharmaceutical pipelines and it broadens ReForm’s potential collaborators,”​ added Sorvillo.

For patients, Sorvillo said the partnership will improve the delivery of therapeutics. “Reform’s formulation technologies enable the conversion of an intravenous dosing to an alternative subcutaneous injection or device-assisted administration,”​ he said.

As per next steps, Sorvillo said the companies will work to coordinate business development activities and identify customers and programs that would benefit from the combination of KBI’s capabilities and Reform’s technology. 

“Reform is also using this collaboration to develop new formulation technologies that can improve the manufacturing, delivery, stability and quality of biologics,”​ he said.

Related news

Show more

Related products

show more

baxter_bloomington_facility_larger

Sterile Injectables Contract Manufacturing

Baxter BioPharma Solutions | 02-Apr-2018 | Product Brochure

Baxter BioPharma Solutions' award-winning facility in Bloomington, Indiana, USA, is a leader in sterile contract manufacturing of injectable products.

lyo_development

Lyophilization Scale-Up and Tech Transfer

Baxter BioPharma Solutions | 12-Mar-2018 | Technical / White Paper

There are few challenges when increasing the scale of production for a solution formulation, but the challenges drastically increase when the formulation...

How will Brexit affect the Pharmaceutical Industry?

How will Brexit affect the Pharmaceutical Industry?

Source BioScience Ltd | 08-Mar-2018 | Technical / White Paper

Have you prepared your strategy for the outcome of Brexit to ensure that you can continue to supply the UK market?
Source BioScience is a CRO with...

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

Related suppliers